Kim D. Janda
Directeur/Bestuurslid bij SORRENTO THERAPEUTICS, INC.
Vermogen: - $ op 31-05-2024
Actieve functies van Kim D. Janda
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SORRENTO THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-04-2012 | - |
Independent Dir/Board Member | 01-04-2012 | - | |
The Scripps Research Institute
The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Corporate Officer/Principal | 01-01-1996 | - |
Worm Institute For Research & Medicine | Directeur/Bestuurslid | 01-01-2005 | - |
Cessation Therapeutics, LLC
Cessation Therapeutics, LLC Pharmaceuticals: MajorHealth Technology Cessation Therapeutics, LLC is a clinical-stage pharmaceutical company that develops immunobiologics to prevent and protect against overdose. The company is based in San Jose, CA. The company's monoclonal antibodies are designed to target fentanyl and future synthetic opioids and other substances. The company has the potential to treat a range of substance use disorders and improve the lives of patients and families affected by the addiction crisis. Cessation was founded in 2018 by Mark Pearson and John D. Harkey, Jr., experienced, successful long-term biotech investors. The CEO is Mark E. Pearson. | Directeur/Bestuurslid | - | - |
Loopbaan van Kim D. Janda
Eerdere bekende functies van Kim D. Janda
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Drug Abuse Sciences | Oprichter | - | - |
CombiChem, Inc.
CombiChem, Inc. Miscellaneous Commercial ServicesCommercial Services CombiChem, Inc. used to provide computational drug recovery services to accelerate the discovery process for new drugs and chemical compounds. The company was founded in 1994 and headquartered in San Diego, CA | Oprichter | - | - |
Opleiding van Kim D. Janda
University of South Florida | Undergraduate Degree |
University of Arizona | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 9 |
Operationeel
Director/Board Member | 3 |
Founder | 2 |
Independent Dir/Board Member | 1 |
Sectoraal
Consumer Services | 5 |
Health Technology | 3 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SORRENTO THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
CombiChem, Inc.
CombiChem, Inc. Miscellaneous Commercial ServicesCommercial Services CombiChem, Inc. used to provide computational drug recovery services to accelerate the discovery process for new drugs and chemical compounds. The company was founded in 1994 and headquartered in San Diego, CA | Commercial Services |
Drug Abuse Sciences | |
Cessation Therapeutics, LLC
Cessation Therapeutics, LLC Pharmaceuticals: MajorHealth Technology Cessation Therapeutics, LLC is a clinical-stage pharmaceutical company that develops immunobiologics to prevent and protect against overdose. The company is based in San Jose, CA. The company's monoclonal antibodies are designed to target fentanyl and future synthetic opioids and other substances. The company has the potential to treat a range of substance use disorders and improve the lives of patients and families affected by the addiction crisis. Cessation was founded in 2018 by Mark Pearson and John D. Harkey, Jr., experienced, successful long-term biotech investors. The CEO is Mark E. Pearson. | Health Technology |
- Beurs
- Insiders
- Kim D. Janda
- Ervaring